News27.10.04 16:27 Age: 6 yrs
Ipsogen signs an agreement with the Cleveland Clinic to identify molecular markers in early stage breast cancer. Category: Breast Cancer
 Marseille, France, Wednesday, 27 October 2004 - Ipsogen announced today that it has signed an agreement with The Cleveland Clinic and Dr. Richard Crownover (Cleveland, USA) to identify molecular markers in early stage breast cancer, which predict patient risk for recurrence. Under this agreement, The Cleveland Clinic and Ipsogen will combine extensive clinical and technical resources to identify prognostic and predictive markers by utilizing large-scale gene expression profiling, respectively. “Dr. Crownover’s team is a global leader in breast cancer management and is pioneering the use of novel, personalized therapeutic modalities to improve clinical management of breast cancer. Applying Ipsogen’s large-scale gene expression profiling will enhance current understanding of the pathobiology and heterogeneity of breast cancer, and may identify diagnostic, prognostic and predictive biomarkers to identify patients at high risk for recurrence...  |
|
